Personalized Medicine (also referred as Precision Medicine) is a tailored approach of deciding and predicting treatment practices based on the molecular analysis of patient’s proteins, metabolites…
Category: Articles
Aug 9
Snippet : Genetic Mutation
Can CRISPR really fix genetic mutation in human embryos? Team of scientists who created controversial blockbuster last year claim that they have fixed a disease-causing mutation in…
Aug 8
Snippet : Migraine
Teva’s migraine drug is expected to launch this year despite the delay in FDA approval Teva Pharmaceutical’s fremanezumab for treating migraine is expected to launch later…
Aug 6
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) – a lesser developed window
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) – a lesser developed window Mucopolysaccharidosis (MPS) is a group of rare, hereditary and incurable “storage diseases”, which is named…
Jul 27
Niemann-Pick disease type C (NPC) -A Rare Cognitive Decline Indication
Niemann-Pick disease type C (NPC) is a lipid storage disease that can present in infants, children, or adults. Neonates can present with ascites and severe liver…
Jul 25
Snippet : Endometriosis
The FDA has approved AbbVie’s Gonadotropin-Releasing Hormone (GnRH) antagonist Elagolix on Tuesday. FDA has given green light to the first oral treatment for endometriosis pain. The drug…
Jul 19
Business Cocktail
Sanofi bags rights to Revolution’s SHP2 cancer drug Sanofi has paid $50 million to work with Revolution Medicines on the development of cancer drugs against SHP2….
Jul 17
Commercial Outcomes – 17/07/2018 (Novartis)
Novartis to Spin-Off Eye Care Device Business Swiss pharmaceutical major, Novartis, has announced it plan to spin-off Alcon, its eye care division, into a separately-traded standalone company. The…
Jul 17
Key Clinical Outcomes- 30/07/2018
AbbVie’s Orilissa for Endometriosis Pain Management Receives FDA Approval AbbVie in cooperation with Neurocrine Biosciences announced that the U.S. FDA approved Orilissa (elagolix), the first and…
Jul 17
Neuroscience Highlights – 17/07/2018
Alkermes Gets FDA approval for Aristada Initio (aripiprazole lauroxil) as Part of Schizophrenia Treatment Combination Alkermes has announced that the U.S. FDA approved ARISTADA INITIO (aripiprazole lauroxil) for the…
